Roquefort Therapeutics (LON:COIL) Shares Down 0.4% – Should You Sell?

by · The Markets Daily

Roquefort Therapeutics plc (LON:COIL – Get Free Report) shares fell 0.4% during mid-day trading on Monday. The company traded as low as GBX 6.80 and last traded at GBX 6.80. 429 shares were traded during mid-day trading, a decline of 100% from the average session volume of 280,132 shares. The stock had previously closed at GBX 6.83.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reissued a “house stock” rating on shares of Roquefort Therapeutics in a report on Monday, September 21st.

Get Our Latest Stock Report on Roquefort Therapeutics

Roquefort Therapeutics Stock Performance

The company has a quick ratio of 3.07, a current ratio of 0.63 and a debt-to-equity ratio of 8.18. The firm has a 50-day simple moving average of GBX 7.43 and a 200 day simple moving average of GBX 9.38. The company has a market cap of £29.45 million, a price-to-earnings ratio of -0.34 and a beta of 0.05.

Roquefort Therapeutics (LON:COIL – Get Free Report) last posted its quarterly earnings data on Monday, September 28th. The company reported GBX (1.66) EPS for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.71%.

Insider Buying and Selling

In related news, insider Stephen Paul West acquired 261,437 shares of Roquefort Therapeutics stock in a transaction that occurred on Monday, September 28th. The stock was purchased at an average price of GBX 8 per share, for a total transaction of £20,914.96. Company insiders own 36.27% of the company’s stock.

About Roquefort Therapeutics

(Get Free Report)

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.

See Also